KYNTRA BIO, INC. 8K

Kyntra Bio amended its royalty financing agreement to substantially reduce future payment obligations and, along with a favorable FibroGen Europe bankruptcy settlement, cut about $80 million of liabilities and extend its cash runway into late 2027.

Kyntra Bio announced that it has amended and restated its royalty financing agreement with NQ Project Phoebus, L.P., materially reducing the maximum aggregate payments owed from $125 million to $65 million in exchange for an accelerated $42.6 million upfront payment that fully returns the investor’s capital and leaves up to $15 million of future royalty-based payments tied to 50% of Astellas-related revenues (excluding Japan), after which all EVRENZO royalties revert to Kyntra. Together with the earlier bankruptcy settlement of its subsidiary FibroGen Europe—where $19.2 million of product development obligations and accrued interest were settled for approximately $0.1 million—these actions reduce future liabilities by about $80 million and support a pro forma cash, cash equivalents, investments, and accounts receivable balance of $53.1 million as of June 30, 2026, extending the company’s cash runway into the fourth quarter of 2027 while it advances its rare disease and oncology pipeline, including FG-3246 and roxadustat.

Filing Facts

CIK

921299

Ticker

-

Form

8K

Source Type

sec

Accession

0001193125-26-377059

Alert Tier

7